Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PTC Therapeutics ( (PTCT) ) just unveiled an update.
PTC Therapeutics has struck a $150 million deal to sell its Rare Pediatric Disease Priority Review Voucher, awarded by the FDA alongside the approval of KEBILIDI™ for AADC deficiency treatment. This transaction highlights PTC’s strategic focus on leveraging innovative therapies for rare disorders and underscores its commitment to maximizing stakeholder value. The deal remains subject to standard closing conditions, including regulatory approvals under antitrust laws.
See more insights into PTCT stock on TipRanks’ Stock Analysis page.
